<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37322633</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">0975-9174</ISSN><JournalIssue CitedMedium="Internet"><Volume>157</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>The Indian journal of medical research</Title><ISOAbbreviation>Indian J Med Res</ISOAbbreviation></Journal><ArticleTitle>Risk factors for clinically significant diffuse parenchymal lung abnormalities persisting after severe COVID-19 pneumonia.</ArticleTitle><Pagination><StartPage>427</StartPage><EndPage>437</EndPage><MedlinePgn>427-437</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijmr.ijmr_2360_22</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; OBJECTIVES" NlmCategory="UNASSIGNED">The risk factors for clinically significant diffuse parenchymal lung abnormalities (CS-DPLA) persisting after severe coronavirus disease 2019 (COVID-19) pneumonia remain unclear. The present study was conducted to assess whether COVID-19 severity and other parameters are associated with CS-DPLA.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The study participants included patients who recovered after acute severe COVID-19 and presented with CS-DPLA at two or six month follow up and control group (without CS-DPLA). Adults volunteers without any acute illness, chronic respiratory illness and without a history of severe COVID-19 were included as healthy controls for the biomarker study. The CS-DPLA was identified as a multidimensional entity involving clinical, radiological and physiological pulmonary abnormalities. The primary exposure was the neutrophil-lymphocyte ratio (NLR). Recorded confounders included age, sex, peak lactate dehydrogenase (LDH), advanced respiratory support (ARS), length of hospital stay (LOS) and others; associations were analyzed using logistic regression. The baseline serum levels of surfactant protein D, cancer antigen 15-3 and transforming growth factor-&#x3b2; (TGF-&#x3b2;) were also compared among cases, controls and healthy volunteers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified 91/160 (56.9%) and 42/144 (29.2%) participants with CS-DPLA at two and six months, respectively. Univariate analyses revealed associations of NLR, peak LDH, ARS and LOS with CS-DPLA at two months and of NLR and LOS at six months. The NLR was not independently associated with CS-DPLA at either visit. Only LOS independently predicted CS-DPLA at two months [adjusted odds ratios (aOR) (95% confidence interval [CI]), 1.16 (1.07-1.25); P&lt;0.001] and six months [aOR (95% CI) and 1.07 (1.01-1.12); P=0.01]. Participants with CS-DPLA at six months had higher baseline serum TGF-&#x3b2; levels than healthy volunteers.</AbstractText><AbstractText Label="INTERPRETATION AND CONCLUSIONS" NlmCategory="UNASSIGNED">Longer hospital stay was observed to be the only independent predictor of CS-DPLA six months after severe COVID-19. Serum TGF-&#x3b2; should be evaluated further as a biomarker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhooria</LastName><ForeName>Sahajal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Siddhant</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaudhary</LastName><ForeName>Shivani</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sehgal</LastName><ForeName>Inderpaul Singh</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhakar</LastName><ForeName>Nidhi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Radiodiagnosis &amp; Imaging, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammad</LastName><ForeName>Nasim</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Riya</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Prabir</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Immunopathology, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Yashwant</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunopathology, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Mandeep</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiodiagnosis &amp; Imaging, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puri</LastName><ForeName>Goverdhan Dutt</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia &amp; Intensive Care, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhalla</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muthu</LastName><ForeName>Valliappan</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>Kuruswamy Thurai</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Ritesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Ashutosh Nath</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Med Res</MedlineTA><NlmUniqueID>0374701</NlmUniqueID><ISSNLinking>0971-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">interstitial lung abnormalities</Keyword><Keyword MajorTopicYN="N">interstitial lung disease</Keyword><Keyword MajorTopicYN="N">long COVID-2019</Keyword><Keyword MajorTopicYN="N">lung fibrosis</Keyword><Keyword MajorTopicYN="N">sequelae</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37322633</ArticleId><ArticleId IdType="pmc">PMC10443720</ArticleId><ArticleId IdType="doi">10.4103/ijmr.ijmr_2360_22</ArticleId><ArticleId IdType="pii">378770</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Montani D, Savale L, Beurnier A, Colle R, No&#xeb;l N, Pham T, et al. Multidisciplinary approach for post-acute COVID-19 syndrome: Time to break down the walls. Eur Respir J. 2021;58:2101090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112007</ArticleId><ArticleId IdType="pubmed">33958429</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M, Maralakunte M, Garg S, Dhooria S, Sehgal I, Bhalla AS, et al. The conundrum of 'long-COVID-19': A narrative review. Int J Gen Med. 2021;14:2491&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214209</ArticleId><ArticleId IdType="pubmed">34163217</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhooria S, Chaudhary S, Sehgal IS, Agarwal R, Arora S, Garg M, et al. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: An open-label, randomised trial (the COLDSTER trial) Eur Respir J. 2022;59:2102930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8850687</ArticleId><ArticleId IdType="pubmed">34887325</ArticleId></ArticleIdList></Reference><Reference><Citation>Besutti G, Giorgi Rossi P, Ottone M, Spaggiari L, Canovi S, Monelli F, et al. Inflammatory burden and persistent CT lung abnormalities in COVID-19 patients. Sci Rep. 2022;12:4270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8914439</ArticleId><ArticleId IdType="pubmed">35277562</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study. Lancet. 2021;398:747&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocconcelli E, Bernardinello N, Giraudo C, Castelli G, Giorgino A, Leoni D, et al. Characteristics and prognostic factors of pulmonary fibrosis after COVID-19 pneumonia. Front Med (Lausanne) 2021;8:823600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8841677</ArticleId><ArticleId IdType="pubmed">35174188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Zhong L, Li H, Guo J, Li Y, Hou X, et al. A follow-up study of lung function and chest computed tomography at 6 months after discharge in patients with coronavirus disease 2019. Can Respir J. 2021;2021:6692409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7881736</ArticleId><ArticleId IdType="pubmed">33628349</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellemons ME, Huijts S, Bek LM, Berentschot JC, Nakshbandi G, Schurink CAM, et al. Persistent health problems beyond pulmonary recovery up to 6 months after hospitalization for COVID-19: A longitudinal study of respiratory, physical, and psychological outcomes. Ann Am Thorac Soc. 2022;19:551&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8996273</ArticleId><ArticleId IdType="pubmed">34582728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamberini L, Tonetti T, Spadaro S, Zani G, Mazzoli CA, Capozzi C, et al. Factors influencing liberation from mechanical ventilation in coronavirus disease 2019: Multicenter observational study in fifteen Italian ICUs. J Intensive Care. 2020;8:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7558552</ArticleId><ArticleId IdType="pubmed">33078076</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou KM, Vasarmidi E, Russell AM, Andrejak C, Crestani B, Delcroix M, et al. European Respiratory Society statement on long COVID follow-up. Eur Respir J. 2022;60:2102174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349784</ArticleId><ArticleId IdType="pubmed">35144991</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastasio F, Barbuto S, Scarnecchia E, Cosma P, Fugagnoli A, Rossi G, et al. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life. Eur Respir J. 2021;58:2004015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7877327</ArticleId><ArticleId IdType="pubmed">33574080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells AU, Devaraj A. Residual lung disease at six-month follow-up CT after COVID-19: Clinical significance is a key issue. Radiology. 2021;301:E406&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8335810</ArticleId><ArticleId IdType="pubmed">34313479</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M, Maralakunte M, Dhooria S. Sequelae of COVID-19 pneumonia: Is it correct to label everything as post-COVID lung fibrosis? J Postgrad Med. 2021;67:224&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8706535</ArticleId><ArticleId IdType="pubmed">34845890</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med. 2008;177:1248&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">18369202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansell DM, Bankier AA, MacMahon H, McLoud TC, M&#xfc;ller NL, Remy J. Fleischner Society: Glossary of terms for thoracic imaging. Radiology. 2008;246:697&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195376</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">16055882</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal AN, Gupta D, Jindal SK. Development of a simple computer program for spirometry interpretation. J Assoc Physicians India. 2002;50:567&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12164412</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: Field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">25359355</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes L, Mesquita AM, Vadala R, Dias A. Reference equation for six minute walk test in healthy Western India population. J Clin Diagn Res. 2016;10:CC01&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4948381</ArticleId><ArticleId IdType="pubmed">27437206</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myll&#xe4;rniemi M, Saarto T. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3:00084&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5731772</ArticleId><ArticleId IdType="pubmed">29255720</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180:1081&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218676</ArticleId><ArticleId IdType="pubmed">32396163</ArticleId></ArticleIdList></Reference><Reference><Citation>Berenguer J, Borobia AM, Ryan P, Rodr&#xed;guez-Ba&#xf1;o J, Bell&#xf3;n JM, Jarr&#xed;n I, et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: The COVID-19 SEIMC score. Thorax. 2021;76:920&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7908055</ArticleId><ArticleId IdType="pubmed">33632764</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325:1074&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905703</ArticleId><ArticleId IdType="pubmed">33625505</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021;299:E177&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AS, Wong AW, Hague CJ, Murphy DT, Johnston JC, Ryerson CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76:402&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">33273023</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey N, Kaushal V, Puri GD, Taneja S, Biswal M, Mahajan P, et al. Transforming a general hospital to an infectious disease hospital for COVID-19 over 2 weeks. Front Public Health. 2020;8:382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7399037</ArticleId><ArticleId IdType="pubmed">32850601</ArticleId></ArticleIdList></Reference><Reference><Citation>Spadaro S, Fogagnolo A, Campo G, Zucchetti O, Verri M, Ottaviani I, et al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit Care. 2021;25:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894238</ArticleId><ArticleId IdType="pubmed">33608030</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: An analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017;5:946&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">29150411</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease &#x2013;A randomised controlled trial. Rheumatol Int. 2020;40:703&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">32239322</ArticleId></ArticleIdList></Reference><Reference><Citation>Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman WS, Lee CT, Pugashetti JV, et al. Circulating plasma biomarkers of survival in antifibrotic-treated patients with idiopathic pulmonary fibrosis. Chest. 2020;158:1526&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545483</ArticleId><ArticleId IdType="pubmed">32450241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong M, Xiong Y, Zhu C, Xu H, Zheng Q, Jiang Y, et al. Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity. BMC Infect Dis. 2021;21:737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8329621</ArticleId><ArticleId IdType="pubmed">34344306</ArticleId></ArticleIdList></Reference><Reference><Citation>Colarusso C, Maglio A, Terlizzi M, Vitale C, Molino A, Pinto A, et al. Post-COVID-19 patients who develop lung fibrotic-like changes have lower circulating levels of IFN-&#x3b2;but higher levels of IL-1&#x3b1;and TGF-&#x3b2;. Biomedicines. 2021;9:1931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8698335</ArticleId><ArticleId IdType="pubmed">34944747</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhooria S, Maturu VN, Talwar D, Kumar S, Handa A, Agrawal PN, et al. A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities. Lung India. 2022;39:254&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9200209</ArticleId><ArticleId IdType="pubmed">35488683</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaramuzzo G, Ronzoni L, Campo G, Priani P, Arena C, La Rosa R, et al. Long-term dyspnea, regional ventilation distribution and peripheral lung function in COVID-19 survivors: A 1 year follow up study. BMC Pulm Med. 2022;22:408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9643983</ArticleId><ArticleId IdType="pubmed">36352423</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>